Compare SNY & VEEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | VEEV |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 39.5B |
| IPO Year | N/A | 2013 |
| Metric | SNY | VEEV |
|---|---|---|
| Price | $48.35 | $224.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 27 |
| Target Price | $61.50 | ★ $299.92 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 01-29-2026 | 11-20-2025 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ 105.93 | 26.69 |
| EPS | ★ 8.67 | 5.13 |
| Revenue | ★ $53,890,648,839.00 | $3,080,246,000.00 |
| Revenue This Year | $1.73 | $17.74 |
| Revenue Next Year | $6.49 | $12.24 |
| P/E Ratio | ★ $5.58 | $43.86 |
| Revenue Growth | N/A | ★ 15.96 |
| 52 Week Low | $44.62 | $201.54 |
| 52 Week High | $60.12 | $310.50 |
| Indicator | SNY | VEEV |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 32.51 |
| Support Level | $48.16 | $221.42 |
| Resistance Level | $48.76 | $225.78 |
| Average True Range (ATR) | 0.63 | 5.12 |
| MACD | 0.06 | 1.98 |
| Stochastic Oscillator | 59.47 | 40.17 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.